Skip to main content
medichelpline
Back to Clinical Feed
Try:
Front ImmunolInfectious Disease

CD38+ NK cells: novel players in immunoregulation

29 May 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

  • CD38 is a transmembrane protein and ectoenzyme that mainly degrades nicotinamide adenine dinucleotide (NAD+). Studies have revealed increased numbers of CD38-expressing NK (CD3-CD38+CD56+) cells in many diseases.
  • CD38+ NK cell proportions in the peripheral blood and synovial fluid are increased in patients with rheumatoid arthritis (RA), and these cells produce high levels of interferon-γ (IFN-γ) and low levels of transforming growth factor-β (TGF-β), suppressing the differentiation of CD4+ T cells to regulatory T cells (Tregs) to disrupt immune tolerance. CD38+ NK cell proportions in the peripheral blood and tumor tissues are also increased in patients with colorectal cancer (CRC).
  • However, CD38+ NK cells produce low levels of IFN-γ and NAD+ and high levels of TGF-β and adenosine (ADO) and can promote Treg differentiation and macrophage polarization to tumor-associated macrophages (TAMs) to interrupt immune surveillance. CD38+ NK cells were not detected in CD38-KO tumor-bearing mice, and their xenograft tumors grew slowly.

Clinical Editorial

Summary

Frontiers in Immunology published a clinical update in Infectious Disease on 29 May 2026.

The item focuses on CD38+ NK cells: novel players in immunoregulation.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.